Inari Medical Inc (NARI)

$54.8

+0.39

(+0.72%)

Market is closed - opens 7 PM, 16 Jul 2024

Performance

  • $53.24
    $55.45
    $54.80
    downward going graph

    2.85%

    Downside

    Day's Volatility :3.99%

    Upside

    1.17%

    downward going graph
  • $36.73
    $71.85
    $54.80
    downward going graph

    32.97%

    Downside

    52 Weeks Volatility :48.88%

    Upside

    23.73%

    downward going graph

Returns

PeriodInari Medical IncSector (Health Care)Index (Russel 2000)
3 Months
40.15%
6.5%
0.0%
6 Months
-6.99%
5.8%
0.0%
1 Year
-4.96%
12.2%
0.0%
3 Years
-35.76%
14.9%
-18.2%

Highlights

Market Capitalization
3.2B
Book Value
$7.71
Earnings Per Share (EPS)
-0.41
Wall Street Target Price
65.42
Profit Margin
-4.54%
Operating Margin TTM
-5.65%
Return On Assets TTM
-0.68%
Return On Equity TTM
-5.41%
Revenue TTM
520.7M
Revenue Per Share TTM
9.05
Quarterly Revenue Growth YOY
23.3%
Gross Profit TTM
339.0M
EBITDA
-783.0K
Diluted Eps TTM
-0.41
Quarterly Earnings Growth YOY
-0.84
EPS Estimate Current Year
-0.48
EPS Estimate Next Year
0.23
EPS Estimate Current Quarter
-0.2
EPS Estimate Next Quarter
-0.17

Analyst Recommendation

Buy
    82%Buy
    17%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Inari Medical Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
15
Hold
3
3
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 19.38%

Current $54.80
Target $65.42

Company Financials

FY18Y/Y Change
Revenue
6.8M
-
Net Income
-10.2M
-
Net Profit Margin
-148.67%
-
FY19Y/Y Change
Revenue
51.1M
↑ 648.7%
Net Income
-1.9M
↓ 81.22%
Net Profit Margin
-3.73%
↑ 144.94%
FY20Y/Y Change
Revenue
139.7M
↑ 173.17%
Net Income
13.8M
↓ 823.03%
Net Profit Margin
9.87%
↑ 13.6%
FY21Y/Y Change
Revenue
277.0M
↑ 98.31%
Net Income
9.8M
↓ 28.64%
Net Profit Margin
3.55%
↓ 6.32%
FY22Y/Y Change
Revenue
383.5M
↑ 38.45%
Net Income
-29.3M
↓ 397.43%
Net Profit Margin
-7.63%
↓ 11.18%
FY23Y/Y Change
Revenue
493.6M
↑ 28.73%
Net Income
-1.6M
↓ 94.41%
Net Profit Margin
-0.33%
↑ 7.3%
Q4 FY22Q/Q Change
Revenue
107.8M
↑ 12.02%
Net Income
-5.8M
↓ 42.89%
Net Profit Margin
-5.38%
↑ 5.17%
Q1 FY23Q/Q Change
Revenue
116.2M
↑ 7.79%
Net Income
-2.2M
↓ 61.75%
Net Profit Margin
-1.91%
↑ 3.47%
Q2 FY23Q/Q Change
Revenue
119.0M
↑ 2.44%
Net Income
2.1M
↓ 194.0%
Net Profit Margin
1.75%
↑ 3.66%
Q3 FY23Q/Q Change
Revenue
126.4M
↑ 6.19%
Net Income
3.2M
↑ 51.65%
Net Profit Margin
2.5%
↑ 0.75%
Q4 FY23Q/Q Change
Revenue
132.1M
↑ 4.53%
Net Income
-4.7M
↓ 247.6%
Net Profit Margin
-3.53%
↓ 6.03%
Q1 FY24Q/Q Change
Revenue
143.2M
↑ 8.4%
Net Income
-24.2M
↑ 418.58%
Net Profit Margin
-16.9%
↓ 13.37%
FY18Y/Y Change
Total Assets
26.9M
-
Total Liabilities
66.3M
-
FY19Y/Y Change
Total Assets
44.5M
↑ 65.59%
Total Liabilities
83.7M
↑ 26.14%
FY20Y/Y Change
Total Assets
214.1M
↑ 380.6%
Total Liabilities
13.8M
↓ 83.47%
FY21Y/Y Change
Total Assets
311.5M
↑ 45.52%
Total Liabilities
72.3M
↑ 422.71%
FY22Y/Y Change
Total Assets
504.2M
↑ 61.82%
Total Liabilities
87.2M
↑ 20.48%
FY23Y/Y Change
Total Assets
674.2M
↑ 33.74%
Total Liabilities
209.3M
↑ 140.19%
Q4 FY22Q/Q Change
Total Assets
504.2M
↑ 3.35%
Total Liabilities
87.2M
↑ 19.84%
Q1 FY23Q/Q Change
Total Assets
506.5M
↑ 0.47%
Total Liabilities
79.8M
↓ 8.44%
Q2 FY23Q/Q Change
Total Assets
525.0M
↑ 3.64%
Total Liabilities
89.3M
↑ 11.94%
Q3 FY23Q/Q Change
Total Assets
548.8M
↑ 4.55%
Total Liabilities
96.7M
↑ 8.25%
Q4 FY23Q/Q Change
Total Assets
674.2M
↑ 22.85%
Total Liabilities
209.3M
↑ 116.48%
Q1 FY24Q/Q Change
Total Assets
661.8M
↓ 1.85%
Total Liabilities
214.5M
↑ 2.49%
FY18Y/Y Change
Operating Cash Flow
-10.9M
-
Investing Cash Flow
-753.0K
-
Financing Cash Flow
26.8M
-
FY19Y/Y Change
Operating Cash Flow
-4.9M
↓ 54.68%
Investing Cash Flow
-3.1M
↑ 317.53%
Financing Cash Flow
10.2M
↓ 61.79%
FY20Y/Y Change
Operating Cash Flow
1.9M
↓ 138.74%
Investing Cash Flow
-55.4M
↑ 1663.26%
Financing Cash Flow
144.1M
↑ 1309.64%
FY21Y/Y Change
Operating Cash Flow
25.5M
↑ 1232.95%
Investing Cash Flow
-51.0M
↓ 7.96%
Financing Cash Flow
4.1M
↓ 97.17%
FY22Y/Y Change
Operating Cash Flow
-14.0M
↓ 154.82%
Investing Cash Flow
-195.2M
↑ 282.61%
Financing Cash Flow
177.1M
↑ 4249.08%
Q4 FY22Q/Q Change
Operating Cash Flow
11.3M
↓ 186.14%
Investing Cash Flow
-33.2M
↓ 348.07%
Financing Cash Flow
-1.7M
↓ 143.53%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.0M
↓ 117.89%
Investing Cash Flow
-4.0M
↓ 87.84%
Financing Cash Flow
2.5M
↓ 246.0%
Q2 FY23Q/Q Change
Operating Cash Flow
9.8M
↓ 584.85%
Investing Cash Flow
-6.1M
↑ 50.38%
Financing Cash Flow
-2.4M
↓ 195.38%

Technicals Summary

Sell

Neutral

Buy

Inari Medical Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inari Medical Inc
Inari Medical Inc
26.76%
-6.99%
-4.96%
-35.76%
28.91%
Stryker Corporation
Stryker Corporation
-4.68%
4.54%
10.03%
27.55%
59.96%
Boston Scientific Corp.
Boston Scientific Corp.
2.4%
29.49%
48.3%
85.32%
86.38%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.03%
20.96%
-3.4%
-16.29%
43.18%
Abbott Laboratories
Abbott Laboratories
-0.47%
-9.49%
-3.78%
-12.38%
23.81%
Medtronic Plc
Medtronic Plc
-3.59%
-10.93%
-11.11%
-38.73%
-22.82%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inari Medical Inc
Inari Medical Inc
NA
NA
NA
-0.48
-0.05
-0.01
NA
7.71
Stryker Corporation
Stryker Corporation
38.74
38.74
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
65.29
65.29
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
38.58
38.58
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.47
32.47
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.24
28.24
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inari Medical Inc
Inari Medical Inc
Buy
$3.2B
28.91%
NA
-4.54%
Stryker Corporation
Stryker Corporation
Buy
$129.3B
59.96%
38.74
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.2B
86.38%
65.29
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$53.9B
43.18%
38.58
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$181.3B
23.81%
32.47
13.96%
Medtronic Plc
Medtronic Plc
Buy
$100.0B
-22.82%
28.24
11.36%

Insights on Inari Medical Inc

  • Increasing Revenue

    Revenue is up for the last 16 quarters, 25.39M → 143.19M (in $), with an average increase of 10.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 3.16M → -24.20M (in $), with an average decrease of 333.1% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 47.1% return, outperforming this stock by 51.3%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 85.3% return, outperforming this stock by 121.1%

Institutional Holdings

  • BlackRock Inc

    14.59%
  • Vanguard Group Inc

    9.63%
  • Franklin Resources Inc

    4.43%
  • Millennium Management LLC

    3.98%
  • AllianceBernstein L.P.

    3.81%
  • State Street Corporation

    3.55%

Corporate Announcements

  • Inari Medical Inc Earnings

    Inari Medical Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

inari medical is a medical device company pioneering devices for the interventional treatment of vascular thrombi and emboli.

Organization
Inari Medical Inc
Employees
1300
CEO
Mr. Andrew J. Hykes
Industry
Health Technology

FAQs